20 articles
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
150-person trial tests whether PRP injections can reduce knee pain and improve function better than placebo in osteoarthritis patients.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
German researchers tested whether 4g daily taurine could slow aging processes in adults 55-75 over 6 months of supplementation.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
New trial tests whether PRP injections can reduce tennis elbow pain better than standard treatments in 72 participants.
A Phase 1 trial of AV-1959R, an Aฮฒ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40โ60.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
Clinical trial tests platelet-rich plasma therapy for shoulder osteoarthritis in 91 patients over 5 months.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Military study tests regenerative PRP injections against placebo for facet joint pain in 91 participants.
